

The Medicines Patent Pool Foundation

Governance Board Meeting Chairman's Summary

29 August 2017



Attendees:

Board Members: Sigrun Møgedal (Chair), Charles Clift (Vice-Chair), Manica Balasegaram, Anna Zakowicz, Anban Pillay, Brian Tempest, Claudia Chamas, Jayashree Watal.

MPP Staff: Greg Perry (Executive Director), Chan Park (General Counsel), Maica Trabanco (Associate Counsel).

The Governance Board of the Medicines Patent Pool thanks the Expert Advisory Group for its report assessing the amendment of the Gilead-MPP Licence Agreement to include bictegravir, expand the territorial scope of the licence, and increase the visibility of Gilead/MPP on the activities performed by third party resellers under the Licence.

The Board has reviewed the EAG report and the proposed amendment of the licence agreement, and agrees with the EAG's assessment that the proposed collaboration is consistent with the MPP's mandate as outlined in its statutes and Memorandum of Understanding with UNITAID, and geographically represents a significant improvement over the status quo.

Therefore, the Board requests the Executive Director to finalize and sign the necessary documents with Gilead to formalize the amendment to the existing Licence Agreement.